Roger A. Krone - Leidos Holdings, Inc.
Management
Great. Hey, thanks, Cai. So our compliant – our guidance, as Jim said, sort of implies flat full year to full year. But as I'm sure you noticed, we're showing growth in Q3 and the implied guidance for Q4 is significantly higher, frankly above 5%. What we found is we've reached our inflection point, we've got growth in third and fourth quarter, but lower level of government outlays resulted in slower ramps on programs, all right, and those would be programs that were new, right, some scheduled delays on existing programs, and I know you're always interested in GENESIS, so I'll come back to that. And then, as I said in my remarks, we probably are starting to see a little bit of tightening in the job market, although we're really being pleased with our hiring, we just need to think about that going forward whether we can hire, continue to hire at that rate. And that's why we elected to lower our guidance a bit. On the DHS GENESIS program, we did begin the wave deployment in Q3 at new sites and I'm sure you read about that. But despite that, there have been some delays in the program as a result of customer decisions to ensure that the IT infrastructure in some of the DHA sites is ready for deployment. They're going to be thoughtful in creating their rollout schedule. They will convert all of their sites as they anticipated in the program. The size of the program, the funding on the program is still intact. We're proud of our performance. There's always reports that come out, we had an IOT&E report that came out during the quarter, which is very similar to the report that we had earlier, which reiterated that change is hard and installing new IT systems in older environments is the challenge that we all thought it was. Frankly, we really like getting these reports. It's good data for us, as we get ready to deploy more broadly across the DHA environment. And I would highlight it usually doesn't come out in these reports that the benefits and enhancements delivered to customers as a result of the GENESIS program, improved patient care, they're seeing more patients, improvement in clinical efficiencies. For instance, there were 1,300 duplicative lab orders that were caught by the DHA's GENESIS system, and improvements in safety, which we're excited about. We increased the new fill on prescriptions in the pharmacies at those facilities. So again, Cai, we're confident about what 2019 looks like and excited about next year. And although we didn't fully anticipate some of these changes in activities and slowdowns in the quarter, we do expect deployment on DHMSM to ramp up in 2019 and beyond, as we always have, and we expect the flow through of our book-to-bill and our backlog to give us a very, very nice fiscal year 2019. Thanks for your question.
Cai von Rumohr - Cowen & Co. LLC: Thank you.